contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


duearity-will-submit-an-application-for-approval-of-a-tinnitus-product-in-the-united-states

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Duearity

Duearity will submit an application for so-called 510(k) clearance by end of November 2022. An FDA approval will allow the company to sell Tinearity G1 in the US. The company has also started...

<div class="mfn-preamble"><p><strong>Duearity will submit an application for so-called 510(k) clearance by end of November 2022. An FDA approval will allow the company to sell Tinearity G1 in the US. The company has also started building a local sales and market organization.</strong></p></div><div class="mfn-body"><p>Duearity has almost completed the work on the technical file to be submitted to the FDA in the US at the end of November and thus apply for 510(k) clearance. The goal is to get an approval at the end of the first half of 2023 and thus be given the permission to sell Tinearity G1 on the American market.</p><p>- We assess that the US will become Duearity's most important market in the future. Tinnitus is a major problem in the United States and receives a great deal of attention, not least because many military personnel are affected. Therefore, it is a big and important step forward when we now apply for approval for sales in the USA, says Fredrik Westman, CEO of Duearity AB.</p><p>Duearity has the started work on building an organization in the US that will handle marketing, sales and distribution. The goal is for an organization to be in place during the first quarter of 2023.</p></div><div class="mfn-footer mfn-contacts mfn-365b0c3c64d7"><p><strong class="mfn-heading-1">For more information, please contact</strong></p><hr><p>Fredrik Westman, CEO<br>+46 738 - 145 215<br>fredrik.westman@duearity.com&nbsp;<br>www.duearity.com</p></div><div class="mfn-footer mfn-about mfn-57c6e976a4c7"><p><strong class="mfn-heading-1">About Duearity AB (publ)</strong></p><hr><p>Duearity is a medtech company that develops and produces solutions aiming to relieve tinnitus symptoms and make everyday life easier for those who suffer from tinnitus. With a deep understanding of the people who have problems with tinnitus, the Company will with intelligent solutions give these people the opportunity to enjoy life. The company will offer the products Tinearity and Tinearity-AI. Tinearity transmits white noise using Bone Conduction Technology to the inner ear in order to relieve symptoms. Tinearity AI will use artificial intelligence to help people anticipate the symptoms and relieve their discomfort. The company's headquarters are located in Malmö, Sweden.<br>www.duearity.com.<br>www.tinearity.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" class="mfn-generated mfn-primary" href="https://storage.mfn.se/961b8ec1-4d58-40ae-af3d-72422be191ca/duearity-will-submit-an-application-for-approval-of-a-tinnitus-product-in-the-united-states.pdf">Duearity will submit an application for approval of a tinnitus product in the United States</a></p></div>

Duearity will submit an application for approval of a tinnitus product in the United States

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Lääkekehityssijoittaminen: Arvonluonti yrityskaupoilla ja lisensointisopimuksilla

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Pysy ajantasalla Inderesin uutiskirjeillä